CLK4 Inhibitors
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cdc2-Like Kinase Inhibitor, TG003 | 300801-52-9 | sc-202528 sc-202528A | 5 mg 25 mg | $139.00 $548.00 | 6 | |
TG003, a Cdc2-Like Kinase Inhibitor, selectively targets CLK4, disrupting its phosphorylation activity and influencing cell cycle regulation. Its unique binding affinity alters the conformational dynamics of CLK4, leading to distinct downstream signaling effects. The compound's interactions with ATP-binding sites modulate kinase activity, affecting substrate specificity and reaction kinetics. Furthermore, TG003's structural characteristics enhance its solubility, facilitating effective cellular uptake and bioavailability. | ||||||
KH CB19 | 1354037-26-5 | sc-362756 sc-362756A | 1 mg 5 mg | $214.00 $612.00 | 1 | |
KH CB19 acts as a potent CLK4 inhibitor, exhibiting a unique mechanism of action through its selective binding to the enzyme's active site. This interaction stabilizes a specific conformation of CLK4, thereby hindering its catalytic function. The compound's distinct molecular structure promotes favorable interactions with surrounding residues, influencing the enzyme's substrate recognition and altering phosphorylation patterns. Additionally, KH CB19 demonstrates enhanced stability in various environments, contributing to its effective modulation of cellular signaling pathways. | ||||||
CX-4945 | 1009820-21-6 | sc-364475 sc-364475A | 2 mg 50 mg | $183.00 $800.00 | 9 | |
CX-4945, also known as silmitasertib, is a multi-kinase inhibitor that targets CLK4 along with other kinases. It has shown promise in research studies that investigate various cancers, including pancreatic cancer. | ||||||